In stroke, one of the events underlying neuronal injury is the interaction of neuronal nitric oxide synthase (nNOS) with postsynaptic density protein 95 (PSD-95) leading to nitric oxide overproduction.

Researchers from the National Research Centre of Egypt and Cairo University have reported the discovery of novel acetylcholinesterase (AChE) inhibitors as candidates for the management of Alzheimer’s disease.

Scientists from the University of Cambridge, Harvard Medical School and collaborators investigated the potential of ubiquitin carboxyl-terminal hydrolase 30 (USP30) inhibition as a therapeutic strategy for restoring mitophagy to achieve neuroprotection in Parkinson’s disease.

Neumora Therapeutics Inc. has announced IND clearance and initiation of a phase I study of NMRA-266 in healthy adults.

Using microglia and an unbiased screening method, investigators have identified almost 60 previously unknown targets for γ-secretase. Investigators from KU Leuven and colleagues published their results in Molecular Cell on Nov. 16, 2023.

Mira Pharmaceuticals Inc. has reported findings on the cognitive enhancing effects of MIRA-1a, an unscheduled novel synthetic tetrahydrocannabinol (THC) analogue, in normal mice.

REV-ERBα (NR1D1) is a circadian transcriptional repressor that plays a role in the regulation of lipid metabolism and macrophage function, and the global deletion of REV-ERBα has been previously linked to increased microglial activation and mitigation of amyloid plaque formation. In the current study, researchers from Washington University in St Louis and affiliated organizations aimed to explore the cell-autonomous effects of microglial REV-ERBα on tau pathology.